Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Action Steps to Address Inequities in Cancer Care Access, Treatment, and Outcomes in Your Community

Premiere Date: Monday, August 15, 2022

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, August 15, 2023
Note: Credit Is No Longer Available

Faculty

Scott Cook, PhD  (he/him/his) Co-Director Advancing Health Equity: Leading Care, Payment, and Systems Transformation A national program of the Robert Wood Quality Improvement and Care Transformation Strategist Department of Diversity, Equity, and Inclusion University of Chicago Medicine and Biological Sciences Chicago, IL

Aung Naing, MD, FACP  (he/him/his) Professor, Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston, TX Editor-in-Chief, Journal of Immunotherapy and Precision Oncology

Ana I. Velázquez Mañana, MD, MSc  Assistant Professor, Division of Hematology Oncology Zuckerberg San Francisco General Hospital Assistant Director of Diversity, Equity, Inclusion and Accessibility UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, CA

Statement of Need

People from racial and ethnic minority populations and those from under-resourced communities are more likely than non-Hispanic White people to encounter obstacles to cancer diagnosis and treatment. In particular, social determinants of health (SDoH) may restrict access to therapies, such as immune checkpoint inhibitors (ICIs). In addition, implicit and explicit biases may impact a patient’s receipt of guideline-recommended care. Strategies to integrate multilevel interventions are needed to provide equitable access to ICI therapy, reduce risk of adverse events, and optimize patient outcomes.

In this Webcast, expert faculty will discuss the treatment obstacles many patients from underserved communities face, especially for cancer therapies, such as ICIs. They will recommend practices clinicians can implement to help their patients overcome barriers to cancer therapies. Finally, faculty will help clinicians develop strategies to make changes on a personal level and within their practice, and suggest ways to break down structural inequities within their community to improve outcomes for their patients.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Develop strategies to reduce health disparities in patients experiencing irAE.

Financial Support

Supported by educational grants from Bristol Myers Squibb and Merck Sharpe & Dohme Corp.

Target Audience

Physicians, PAs, nurse practitioners, nurses, nurse navigators, pharmacists, social workers, and case managers specializing in oncology, emergency medicine and/or primary care

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring Material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Cook reports no financial relationships.

Dr. Naing reports the following financial relationships:

Research Support: Amplimmune, Inc.; Arcus Biosciences, Inc.; ARMO BioSciences, Inc.; Atterocor, Inc.; Baxalta (I); Bristol Myers Squibb Company; Calithera Biosciences, Inc.; Chao Physician-Scientist Awards (I), Baylor College of Medicine; CytomX Therapeutics, Inc.; EMD Serono Inc.; Healios Oncology Nutrition, LLC; Immune Deficiency Foundation (I); ImmuneOncia Therapeutics, Inc.; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; MedImmune; Lilly; Merck & Co., Inc.; Neon Therapeutics; NeoImmuneTech; National Cancer Institute (NCI); Novartis; Pfizer Inc.; PsiOxus Therapeutics; Regeneron Pharmaceuticals In; Surface Oncology; and TopAlliance BioSciences Inc.

Other Financial or Material Support: (Travel, accommodations, expenses) ARMO Biosciences, Inc.

Dr. Velázquez Mañana reports the following financial relationships:

Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc.

Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology

The following peer reviewer and CME Outfitters staff have no financial relationships:

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)

David Modrak, PhD (planning committee)

Kathleen Blake, PhD (planning committee)

Thomas Mitchell (planning committee)

Sandra Caballero, PharmD (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).